IL17A and vitiligo: A recent case report describes the onset of vitiligo after the administration of adalimumab for psoriasis treatment [76], leading to its suspension and the initiation of secukinumab, an anti-interleukin-17A monoclonal antibody approved for psoriasis treatment.